The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

被引：22

作者：

Falay, Mesude ^{[1
]}

Ozturk, Berna Afacan ^{[1
]}

Gunes, Kursad ^{[1
]}

Kalpakci, Yasin ^{[1
]}

Dagdas, Simten ^{[1
]}

Ceran, Funda ^{[1
]}

Ozet, Gulsum ^{[1
]}

机构：

[1] Univ Minist Hlth, Ankara Numune Training & Res Hosp, Clin Hematol, Ankara, Turkey

来源：

TURKISH JOURNAL OF HEMATOLOGY | 2018年 / 35卷 / 02期

关键词：

Chronic lymphocytic leukemia; Mantle cell lymphoma; Immunophenotyping; CD200; CD43; CHRONIC LYMPHOPROLIFERATIVE DISORDERS; SCORING SYSTEM; CD38; EXPRESSION; FLOW-CYTOMETRY; CLASSIFICATION; DISTINCTION; ABERRATIONS;

D O I：

10.4274/tjh.2017.0085

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: Atypical chronic lymphocytic leukemia (CLL) is most frequently confused with mantle cell lymphoma (MCL). Several markers may contribute to the diagnosis of CLL. However, there is no consensus on which markers are needed to be used in flow cytometry for the diagnosis of CLL. The aim of the present study was to investigate the role of CD43 and CD200 markers in the differential diagnosis between CLL and MCL. Materials and Methods: To address this issue, 339 consecutive patients with CLL and MCL were included in the flow cytometry lymphoproliferative disease panel for evaluation of CD43 and CD200 expressions, but not in the Matutes scoring system. Results: CD200 was expressed in 97.3% of atypical CLL cases, whereas it was dimly expressed in only 6.1% of MCL cases. CD43 expression was 95.7% in atypical CLL cases. In the MCL cases, its expression rate was 39.4%. Conclusion: CD43 and CD200 were found to be more valuable markers than CD22, CD79b, and FMC7. CD43 and CD200 could also be considered as definitive markers in atypical CLL patients, for whom the Matutes scoring system remains ineffective.

引用

页码：94 / 98

页数：5

共 27 条

[11]

Gong JZ, 2001, AM J CLIN PATHOL, V116, P893

[12] CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease [J].

Hamblin, TJ ;

Orchard, JA ;

Ibbotson, RE ;

Davis, Z ;

Thomas, PW ;

Stevenson, FK ;

Oscier, DG .

BLOOD, 2002, 99 (03) :1023-1029

[13] World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997 [J].

Harris, NL ;

Jaffe, ES ;

Diebold, J ;

Flandrin, G ;

Muller-Hermelink, HK ;

Vardiman, J ;

Lister, TA ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3835-3849

[14] Cell surface CD43 determination improves diagnostic precision in late B-cell diseases [J].

Jung, G ;

Eisenmann, JC ;

Thiébault, S ;

Hénon, P .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) :496-499

[15]

Kaleem Z, 2006, ARCH PATHOL LAB MED, V130, P1850

[16]

Kilo MN, 1996, AM J CLIN PATHOL, V105, P451

[17] The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma [J].

Kraus, Teresa S. ;

Sillings, Christine N. ;

Saxe, Debra F. ;

Li, Shiyong ;

Jaye, David L. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (02) :271-277

[18] VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia [J].

Kröber, A ;

Seiler, T ;

Benner, A ;

Bullinger, L ;

Brückle, E ;

Lichter, P ;

Döhner, H ;

Stilgenbauer, S .

BLOOD, 2002, 100 (04) :1410-1416

[19] Uncovering clinically relevant phenotypic variations in malignancies - CD23 in mantle cell lymphoma [J].

Kroft, Steven. H. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (02) :159-161

[20] CD38 as a prognostic marker in CLL [J].

Matrai, Z .

HEMATOLOGY, 2005, 10 (01) :39-46

← 1 2 3 →